Imaging of prostate specific membrane antigen (PSMA) targeted radiotracers appears to be useful in detecting biochemically recurrent prostate cancer at low prostate-specific antigen (PSA) levels, suggest the results of a systematic review and meta-analysis.
Patients referred to home hospice care following non-cancer diagnoses had their preventative medications significantly reduced between admission and death, though this did not apply to patients with cancer referred to hospice care, a retrospective study from Singapore showed.
Symptomatic pericardial effusions are most commonly caused by cancer and iatrogenic complications, results of a Singapore study in an academic medical centre have found. Nonetheless, success rate is high and complications are relatively low in pericardiocentesis.
intensity is significantly associated with increased relapse, decreased
disease-free survival (DFS), and decreased overall survival (OS) in acute
myeloid leukaemia (AML) patients with measurable residual disease (MRD), a new
analysis of a phase III randomized clinical trial has shown.
The combination of TAS-118 and oxaliplatin led to significantly greater survival compared with the S-1 and cisplatin combination in patients with metastatic or recurrent HER2-negative gastric cancer, the phase III SOLAR* study showed.
Disease-free survival (DFS) at 3 years was comparable between patients with locally advanced gastric cancer who underwent laparoscopic distal gastrectomy and open distal gastrectomy, pointing to the noninferiority of the laparoscopic procedure to the open one, according to the CLASS-01* study.
Reducing the dose of regorafenib did little to affect the overall tolerability of the drug in patients with metastatic colorectal cancer (mCRC), according to the phase II REARRANGE* trial presented at ESMO GI 2019.
The survival benefit with ramucirumab was consistent in patients with advanced hepatocellular carcinoma (HCC) and high alpha-fetoprotein (AFP) levels regardless of whether they were previously treated with transarterial chemoembolization (TACE), a post hoc analysis of pooled data from the REACH/REACH-2 studies shows.
Augmenting the triple chemotherapeutic regimen FOLFOXIRI* with bevacizumab demonstrated favourable efficacy regardless of age and gender in patients with unresectable metastatic colorectal cancer (mCRC), according to data presented at the ESMO World Congress on Gastrointestinal Cancer (ESMO GI) 2019.
Adding bevacizumab to trifluridine/tipiracil (FTD/TPI) significantly improves progression-free survival (PFS) and overall survival (OS) compared with FTD/TPI in patients with chemorefractory metastatic colorectal cancer (mCRC), according to a study presented at ESMO GI 2019.
The addition of radiation therapy to chemotherapy does not provide a relapse-free survival (RFS) advantage over chemotherapy only in stage III or IVA endometrial cancer, according to the phase III GOG 258* trial.
Treatment with metformin does not appear to provide an additional benefit of reducing the incidence of cancers, excluding those of the prostate and pancreas, in patients with diabetes, as reported in a study.